AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

The 2022 yearbook of Neurorestoratology

Hongyun Huanga( )John R. BachbHari Shanker SharmacHooshang SaberidSang Ryong JeoneXiaoling GuofAshok ShettygZiad HawamdehhAlok SharmaiKlaus von WildjDario SiniscalcokPaul R. SanberglYong HumMengzhou XuenLin ChenoFabin HanpAli OtomqJianzhong HurQiqing Zhangs
Beijing Hongtianji Neuroscience Academy, Beijing, 100143, China
Department of Physical Medicine and Rehabilitation, Center for Ventilator Management Alternatives, University Hospital of Newark, Newark, NJ, 07102, USA
Intensive Experimental CNS Injury and Repair, Department of Surgical Sciences, University Hospital, Uppsala University, Uppsala, Sweden
Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Kyung Hee University, Seoul, South Korea
Department of Neurology, The 981 Hospital of the Chinese People's Liberation Army Joint Logistics Support Force, Chengde, 067000, Hebei, China
Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M University, USA
School of Medicine, The University of Jordan, Amman, Jordan
Department of Neurosurgery, LTM Medical College, LTMG Hospital, Mumbai, India
Kvw Neuroscience, WWU Munster, Munster, Germany
Department of Experimental Medicine University of Campania “Luigi Vanvitelli”, Via S. Maria di Costantinopoli 16, 80138, Naples, Italy
Center of Excellence for Aging & Brain Repair, Department of Neurosurgery & Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, 33612, Florida, USA
Department of Orthopaedics and Traumatology, The University of Hong Kong, Hong Kong, China
The Department of Cerebrovascular Diseases and, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, Henan, China
Department of Neurosurgery, Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Beijing, 100007, China
The Institute for Stem Cells and Regenerative Medicine, Shandong University/Affiliated Liaocheng Hospital, Liaocheng, 252000, Shandong, China
Royal Specialty Center for Spine & M-Skeletal Disorders, Amman, Jordan
Department of Spine Surgery at Xiangya Hospital of Central South University, Changsha City, China
Institute of Biomedical Engineering, Chinese Academy Medical Sciences & Peking Union Medical College, Beijing, China
Show Author Information

Abstract

There was much progress in the field of Neurorestoratology in the year of 2022. It included highlighting advances in understanding the pathogenesis of neurological diseases, neurorestorative mechanisms, and clinical treatments as compiled in the 2022 yearbook of Neurorestoratology. There is still controversy about whether amyloid β-protein and tau protein deposition are the reasons for or the results of Alzheimer's disease (AD) pathology. The fabricated images in important key articles that speculated on the reasons for AD pathogenesis were found. Cholinergic deficiency and decrease or loss in strength of glutamatergic synapse, limited or failing bidirectional cholinergic upregulation in early cognitive impairment, or progressive posterior-to-anterior cortical cholinergic denervation could result in the appearance of AD. Exploration of neurorestorative mechanisms were found in more detail ways in neuromodulation, immunomodulation, neurogenesis, neural network or circuitry reconstruction, neuroprotection, nervous structural repair, and neuroplasticity. Several kinds of cell therapies for neurological diseases showed neurorestorative effects in open-label and/or non-randomized clinical studies or trials. However, mesenchymal stromal cells and mononuclear cells did not demonstrate neurorestorative effects or improve the quality of life for patients with neurodegenerative diseases or neurotrauma including stroke, spinal cord injury (SCI), and amyotrophic lateral sclerosis in randomized, double-blind, placebo-controlled clinical trials (RDPCTs). Clinical treatments through neurostimulation/neuromodulation and the brain-computer/machine interface yielded positive results in AD, Parkinson's disease, stroke, SCI, cerebral palsy, and other diseases in RDPCTs. Neurorestorative surgery, pharmaceutical neurorestorative therapy and other interventions have demonstrated neurorestorative effects for various considered incurable neurological diseases in RDPCTs. Thus, this year, additional guidelines, assessment scales, and standards were set up or revised. These included guidelines of clinical neurorestorative treatments for brain trauma (2022 China version), clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022), SCI or dysfunction quality of life rating scale (SCIDQLRS) (IANR 2022 version). Neurorestorative effects of varying therapeutic strategies with higher standards of evidence-based medicine are now benefiting patients with currently incurable neurological diseases. Hopefully some of them may become routine therapeutic interventions for patients with these diseases in the near future.

References

1

Piller C. Blots on a field? Science. 2022;377(6604):358-363.

2

Yang H, Yang XL, Yan SL, et al. Effect of acetylcholine deficiency on neural oscillation in a brainstem-thalamus-cortex neurocomputational model related with Alzheimer's disease. Sci Rep. 2022;12(1):14961.

3

Dong H, Yang XL, Sun ZK. How glutamatergic synapse loss affects the firing rhythm of DG-CA3 model related with Alzheimer's disease. Cogn Neurodyn. 2022;16(1):167-181.

4

van der Zee S, Kanel P, Gerritsen MJJ, et al. Altered cholinergic innervation in de novo Parkinson's disease with and without cognitive impairment. Mov Disord. 2022;37(4):713-723.

5

Bohnen NI, Roytman S, Kanel P, et al. Progression of regional cortical cholinergic denervation in Parkinson's disease. Brain Commun. 2022;4(6):fcac320.

6

Guerra A, Colella D, Giangrosso M, et al. Driving motor cortex oscillations modulates bradykinesia in Parkinson's disease. Brain. 2022;145(1):224-236.

7

Iordan AD, Ryan S, Tyszkowski T, et al. High-definition transcranial direct current stimulation enhances network segregation during spatial navigation in mild cognitive impairment. Cereb Cortex. 2022;32(22):5230-5241.

8

Zhang YC, Li CX, Chen DQ, et al. Repeated high-definition transcranial direct current stimulation modulated temporal variability of brain regions in core neurocognitive networks over the left dorsolateral prefrontal cortex in mild cognitive impairment patients. J Alzheimers Dis. 2022;90(2):655-666.

9

Visweswaran M, Hendrawan K, Massey JC, et al. Sustained immunotolerance in multiple sclerosis after stem cell transplant. Ann Clin Transl Neurol. 2022;9(2):206-220.

10

Hoang T, Kim DW, Appel H, et al. Genetic loss of function of Ptbp1 does not induce glia-to-neuron conversion in retina. Cell Rep. 2022;39(11):110849.

11

Zhou Y, Su YJ, Li SY, et al. Molecular landscapes of human hippocampal immature neurons across lifespan. Nature. 2022;607(7919):527-533.

12

Gu X, Wang JH, Jiang XD. miR-124- and let-7-mediated reprogram of human fibroblasts into SST interneurons. ACS Chem Neurosci. 2022;13(18):2755-2765.

13

Zhao JY, Li YY, Zhang X, et al. Alteration of network connectivity in stroke patients with apraxia of speech after tDCS: a randomized controlled study. Front Neurol. 2022;13:969786.

14

Kadir RRA, Alwjwaj M, Bayraktutan U. Treatment with outgrowth endothelial cells protects cerebral barrier against ischemic injury. Cytotherapy. 2022;24(5):489-499.

15

Kaur H, Sarmah D, Datta A, et al. Endovascular stem cell therapy promotes neuronal remodeling to enhance post stroke recovery by alleviating endoplasmic reticulum stress modulated by BDNF signaling. Stem Cell Rev Rep. 2023;19(1):264-274.

16

Sarmah D, Datta A, Kaur H, et al. Sirtuin-1 - mediated NF-κB pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke. Stem Cell Rev and Rep. 2022;18(2):821-838.

17

Kodali M, Madhu LN, Reger RL, et al. Intranasally administered human MSC-derived extracellular vesicles inhibit NLRP3-p38/MAPK signaling after TBI and prevent chronic brain dysfunction. Brain Behav Immun. 2023;108: 118-134.

18

Kim HY, Yoon HH, Seong H, et al. Preventive effects of nano-graphene oxide against Parkinson's disease via reactive oxygen species scavenging and anti-inflammation. BMB Rep. 2023;56(2):202-207.

19

Tereshenko V, Dotzauer DC, Luft M, et al. Autonomic nerve fibers aberrantly reinnervate denervated facial muscles and alter muscle fiber population. J Neurosci. 2022;42(44):8297-8307.

20

Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.

21

Smirnov VA, Radaev SM, Morozova YV, et al. Systemic administration of allogeneic cord blood mononuclear cells in adults with severe acute contusion spinal cord injury: phase 1/2a pilot clinical study-safety and primary efficacy evaluation. World Neurosurg. 2022;161:e319-e338.

22

Saini R, Pahwa B, Agrawal D, et al. Efficacy and outcome of bone marrow derived stem cells transplanted via intramedullary route in acute complete spinal cord injury - a randomized placebo controlled trial. J Clin Neurosci. 2022;100:7-14.

23

Milczarek O, Kwiatkowski S, Swadźba J, et al. Use of multiple Wharton jelly mesenchymal stem cell transplants in treatment of incomplete spinal cord injury: a case report. Exp Clin Transplant. 2022;20(9):878-882.

24

Ahn H, Lee SY, Jung WJ, et al. Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: a case report and review of literature. World J Stem Cells. 2022;14(4):303-309.

25

Chen D, Xi HT, Tan K, et al. Recovering voiding and sex function in a patient with chronic complete spinal cord injury by olfactory ensheathing cell transplantation. Case Rep Neurol Med. 2022;2022:9496652.

26

de Celis-Ruiz E, Fuentes B, Alonso de Leciñana M, et al. Final results of allogeneic adipose tissue-derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase Ⅱ, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. Cell Transplant. 2022;31, 9636897221083863.

27

Baak LM, Wagenaar N, van der Aa NE, et al. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in The Netherlands (PASSIoN): a first-in-human, open-label intervention study. Lancet Neurol. 2022;21(6):528-536.

28

Kikuchi H, Saitoh S, Tsuno T, et al. Safety and feasibility of autologous cord blood infusion for improving motor function in young children with cerebral palsy in Japan: a single-center study. Brain Dev. 2022;44(10):681-689.

29

Sun JM, Case LE, McLaughlin C, et al. Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: an open-label, randomized trial. Dev Med Child Neurol. 2022;64(12):1477-1486.

30

Maric DM, Radomir M, Milankov Z, et al. Encouraging effect of autologous bone marrow aspirate concentrate in rehabilitation of children with cerebral palsy. Eur Rev Med Pharmacol Sci. 2022;26(7):2330-2342.

31

Cox Jr CS, Juranek J, Kosmach S, et al. Autologous cellular therapy for cerebral palsy: a randomized, crossover trial. Brain Commun. 2022;4(3):fcac131.

32

Zarrabi M, Akbari MG, Amanat M, et al. The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial. BMC Neurol. 2022;22(1):123.

33

Amanat M, Majmaa A, Zarrabi M, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther. 2021;12(1):439.

34

Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65(3):291-302.

35

Baloh RH, Johnson JP, Avalos P, et al. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial. Nat Med. 2022;28(9):1813-1822.

36

Lunetta C, Lizio A, Cabona C, et al. A phase Ⅰ/Ⅱa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis. J Neurol. 2022;269(10):5337-5346.

37

Mariottini A, Bulgarini G, Forci B, et al. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis. Eur J Neurol. 2022;29(6):1708-1718.

38

Villarreal-Martinez L, MartÍnez-Garza LE, Rodriguez-Sanchez IP, et al. Correlation between CD133+ stem cells and clinical improvement in patients with autism spectrum disorders treated with intrathecal bone marrow-derived mononuclear cells. Innov Clin Neurosci. 2022;19(4/5/6):78-86.

39

Nguyen Thanh L, Hoang VT, Le Thu H, et al. Human umbilical cord mesenchymal stem cells for severe neurological sequelae due to anti-N-methyl-d-aspartate receptor encephalitis: first case report. Cell Transplant. 2022;31, 9636897221110876.

40

Quintero JE, Slevin JT, Gurwell JA, et al. Direct delivery of an investigational cell therapy in patients with Parkinson's disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design. BMJ Neurol Open. 2022;4(2), e000301.

41

Wang YL, Guo XL, Liu J, et al. Olfactory ensheathing cells in chronic ischemic stroke: a phase 2, double-blind, randomized, controlled trial. J Neurorestoratol. 2020;8(3):182-193.

42

Sprugnoli G, Munsch F, Cappon D, et al. Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer's disease. Alzheimer's Res Ther. 2021;13(1):203.

43

Benussi A, Cantoni V, Grassi M, et al. Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer's disease. Ann Neurol. 2022;92(2):322-334.

44

Zhou DS, Li A, Li XX, et al. Effects of 40 Hz transcranial alternating current stimulation (tACS) on cognitive functions of patients with Alzheimer's disease: a randomised, double-blind, sham-controlled clinical trial. J Neurol Neurosurg Psychiatry. 2022;93(5):568-570.

45

Chan DE, Suk HJ, Jackson BL, et al. Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: results of feasibility and pilot studies. PLoS One. 2022;17(12), e0278412.

46

Dhaynaut M, Sprugnoli G, Cappon D, et al. Impact of 40 Hz transcranial alternating current stimulation on cerebral tau burden in patients with Alzheimer's disease: a case series. J Alzheim Dis. 2022;85(4):1667-1676.

47

Mencarelli L, Monti L, Romanella S, et al. Local and distributed fMRI changes induced by 40 Hz gamma tACS of the bilateral dorsolateral prefrontal cortex: a pilot study. Neural Plast. 2022;2022:6197505.

48

Varastegan S, Kazemi R, Rostami R, et al. Remember NIBS? tACS improves memory performance in elders with subjective memory complaints. GeroScience. 2023;45(2):851-869.

49

Liu Y, Tang C, Wei KL, et al. Transcranial alternating current stimulation combined with sound stimulation improves the cognitive function of patients with Alzheimer's disease: a case report and literature review. Front Neurol. 2022;13:962684.

50

Hu Y, Jia Y, Sun Y, et al. Efficacy and safety of simultaneous rTMS-tDCS over bilateral angular gyrus on neuropsychiatric symptoms in patients with moderate Alzheimer's disease: a prospective, randomized, sham-controlled pilot study. Brain Stimul. 2022;15(6):1530-1537.

51

Zhou X, Wang Y, Lv S, et al. Transcranial magnetic stimulation for sleep disorders in Alzheimer's disease: a double-blind, randomized, and sham-controlled pilot study. Neurosci Lett. 2022;766:136337.

52

Andrade SM, Machado DGDS, Silva-Sauerc LD, et al. Effects of multisite anodal transcranial direct current stimulation combined with cognitive stimulation in patients with Alzheimer's disease and its neurophysiological correlates: a double-blind randomized clinical trial. Neurophysiol Clin. 2022;52(2):117-127.

53

Satorres E, Escudero Torrella J, Real E, et al. Home-based transcranial direct current stimulation in mild neurocognitive disorder due to possible Alzheimer's disease. A randomised, single-blind, controlled-placebo study. Front Psychol. 2022;13:1071737.

54

Koch G, Casula EP, Bonnì S, et al. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain. 2022;145(11):3776-3786.

55

Zhang XQ, Ren HX, Pei ZA, et al. Dual-targeted repetitive transcranial magnetic stimulation modulates brain functional network connectivity to improve cognition in mild cognitive impairment patients. Front Physiol. 2022;13:1066290.

56

Zhao CG, Li DW, Kong YJ, et al. Transcranial photobiomodulation enhances visual working memory capacity in humans. Sci Adv. 2022;8(48), eabq3211.

57

Qu XJ, Li LX, Zhou XH, et al. Repeated transcranial photobiomodulation improves working memory of healthy older adults: behavioral outcomes of poststimulation including a three-week follow-up. Neurophotonics. 2022;9(3), 035005.

58

Papi S, Allahverdipour H, Jahan A, et al. The effect of transcranial photobiomodulation on cognitive function and attentional performance of older women with mild cognitive impairment: a randomized controlled trial. Prz Menopauzalny. 2022;21(3):157-164.

59

Cheung MC, Lee TL, Sze SL, et al. Photobiomodulation improves frontal lobe cognitive functions and mental health of older adults with non-amnestic mild cognitive impairment: case studies. Front Psychol. 2022;13:1095111.

60

Saitoh Y, Hosomi K, Mano T, et al. Randomized, sham-controlled, clinical trial of repetitive transcranial magnetic stimulation for patients with Alzheimer's dementia in Japan. Front Aging Neurosci. 2022;14:993306.

61

Na Y, Kim J, Lee SH, et al. Multichannel transcranial direct current stimulation combined with treadmill gait training in patients with Parkinson's disease: a pilot study. Front Neurol. 2022;13:804206.

62

Wong PL, Yang YR, Huang SF, et al. Transcranial direct current stimulation on different targets to modulate cortical activity and dual-task walking in individuals with Parkinson's disease: a double blinded randomized controlled trial. Front Aging Neurosci. 2022;14:807151.

63

Park JE, Hallett M, Jang HR, et al. Effects of anodal stimulation and motor practice on limb-kinetic apraxia in Parkinson's disease. Exp Brain Res. 2022;240(4):1249-1256.

64

De Icco R, Putortì A, Allena M, et al. Non-invasive neuromodulation in the rehabilitation of Pisa syndrome in Parkinson's disease: a randomized controlled trial. Front Neurol. 2022;13:849820.

65

Ruggiero F, Dini M, Cortese F, et al. Anodal transcranial direct current stimulation over the cerebellum enhances sadness recognition in Parkinson's disease patients: a pilot study. Cerebellum. 2022;21(2):234-243.

66

Wong PL, Yang YR, Tang SC, et al. Comparing different montages of transcranial direct current stimulation on dual-task walking and cortical activity in chronic stroke: double-blinded randomized controlled trial. BMC Neurol. 2022;22(1):119.

67

Pavlova EL, Semenov RV, Pavlova-Deb MP, et al. Transcranial direct current stimulation of the premotor cortex aimed to improve hand motor function in chronic stroke patients. Brain Res. 2022;1780:147790.

68

Kaminski E, Maudrich T, Bassler P, et al. tDCS over the primary motor cortex contralateral to the trained hand enhances cross-limb transfer in older adults. Front Aging Neurosci. 2022;14:935781.

69

Huang YJ, Wang SM, Chen C, et al. High-definition transcranial direct current with electrical Theta burst on post-stroke motor rehabilitation: a pilot randomized controlled trial. Neurorehabilitation Neural Repair. 2022;36(9):645-654.

70

Prathum T, Piriyaprasarth P, Aneksan B, et al. Effects of home-based dual-hemispheric transcranial direct current stimulation combined with exercise on upper and lower limb motor performance in patients with chronic stroke. Disabil Rehabil. 2022;44(15):3868-3879.

71

Kashoo FZ, Al-Baradie RS, Alzahrani M, et al. Effect of transcranial direct current stimulation augmented with motor imagery and upper-limb functional training for upper-limb stroke rehabilitation: a prospective randomized controlled trial. Int J Environ Res Publ Health. 2022;19(22):15199.

72

Wei YY, Koh CL, Hsu MJ, et al. Effects of transcranial direct current stimulation combined with neuromuscular electrical stimulation on upper extremity motor function in patients with stroke. Am J Phys Med Rehabil. 2021;101(2):145-151.

73

Lee SA, Cha H. The effect of clinical application of transcranial direct current stimulation combined with non-immersive virtual reality rehabilitation in stroke patients. Technol Health Care. 2022;30(1):117-127.

74

Zhao L, Liu ZB, Sun QF, et al. Effect of transcranial direct current stimulation combined with a smart hand joint training device on hand dysfunction in patients with early stroke. Folia Neuropathol. 2022;60(2):177-184.

75

Guo LY, Xu S, Zhang Y, et al. Effects of transcranial direct current stimulation and neuromuscular joint facilitation on upper limb motor disorders for stroke patients. Alternative Ther Health Med. 2023;29(2):120-124.

76

Garrido MM, Álvarez EE, Acevedo PF, et al. Early transcranial direct current stimulation with modified constraint-induced movement therapy for motor and functional upper limb recovery in hospitalized patients with stroke: a randomized, multicentre, double-blind, clinical trial. Brain Stimul. 2023;16(1):40-47.

77

Ehsani F, Mortezanejad M, Yosephi MH, et al. The effects of concurrent M1 anodal tDCS and physical therapy interventions on function of ankle muscles in patients with stroke: a randomized, double-blinded sham-controlled trial study. Neurol Sci. 2022;43(3):1893-1901.

78

Klomjai W, Aneksan B, Chotik-Anuchit S, et al. Effects of different montages of transcranial direct current stimulation on haemodynamic responses and motor performance in acute stroke: a randomized controlled trial. J Rehabil Med. 2022;54, jrm00331.

79

Qurat-Ul-Ain, Ahmad Z, Ishtiaq S, et al. Short term effects of anodal cerebellar vs. anodal cerebral transcranial direct current stimulation in stroke patients, a randomized control trial. Front Neurosci. 2022;16:1035558.

80

Morone G, Capone F, Iosa M, et al. May dual transcranial direct current stimulation enhance the efficacy of robot-assisted therapy for promoting upper limb recovery in chronic stroke? Neurorehabilitation Neural Repair. 2022;36(12):800-809.

81

Liu CY, Russin J, Adelson DP, et al. Vagus nerve stimulation paired with rehabilitation for stroke: implantation experience from the VNS-REHAB trial. J Clin Neurosci. 2022;105:122-128.

82

Metzger SL, Liu JR, Moses DA, et al. Generalizable spelling using a speech neuroprosthesis in an individual with severe limb and vocal paralysis. Nat Commun. 2022;13(1):6510.

83

Lee SH, Kim SS, Lee BH. Action observation training and brainecomputer interface controlled functional electrical stimulation enhance upper extremity performance and cortical activation in patients with stroke: a randomized controlled trial. Physiother Theory Pract. 2022;38(9):1126-1134.

84

Zhao CG, Ju F, Sun W, et al. Effects of training with a brainecomputer interface-controlled robot on rehabilitation outcome in patients with subacute stroke: a randomized controlled trial. Neurol Ther. 2022;11(2):679-695.

85

Li X, Wang L, Miao S, et al. Sensorimotor rhythm-brain computer interface with audio-cue, motor observation and multisensory feedback for upper-limb stroke rehabilitation: a controlled study. Front Neurosci. 2022;16:808830.

86

Ko MH, Yoon JY, Jo YJ, et al. Home-based transcranial direct current stimulation to enhance cognition in stroke: randomized controlled trial. Stroke. 2022;53(10):2992-3001.

87

Xie XH, Hu PP, Tian YH, et al. Transcranial alternating current stimulation enhances speech comprehension in chronic post-stroke aphasia patients: a single-blind sham-controlled study. Brain Stimul. 2022;15(6):1538-1540.

88

Wong MN, Baig FN, Chan YK, et al. Transcranial direct current stimulation over the primary motor cortex improves speech production in post-stroke dysarthric speakers: a randomized pilot study. PLoS One. 2022;17(10), e0275779.

89

Cid-Fernández S, Rivas-Fernández MÁ, Varela-López B, et al. Combined anodal transcranial direct current stimulation and behavioural naming treatment improves language performance in patients with post-stroke aphasia. Brain Inj. 2022;36(8):1039-1045.

90

Msigwa SS, Li Y, Cheng XL, et al. Combining electroacupuncture and transcranial direct current stimulation as an adjuvant therapy enhances spontaneous conversation and naming in subacute vascular aphasia: a retrospective analysis. J Integr Med. 2022;20(3):244-251.

91

Mao HW, Lyu Y, Li Y, et al. Clinical study on swallowing function of brainstem stroke by tDCS. Neurol Sci. 2022;43(1):477-484.

92

Farpour S, Asadi-Shekaari M, Haghighi AB, et al. Improving swallowing function and ability in post stroke dysphagia: a randomized clinical trial. Dysphagia. 2023;38(1):330-339.

93

Rao JZ, Li F, Zhong LD, et al. Bilateral cerebellar intermittent Theta burst stimulation combined with swallowing speech therapy for dysphagia after stroke: a randomized, double-blind, sham-controlled, clinical trial. Neurorehabilitation Neural Repair. 2022;36(7):437-448.

94

Dong LH, Pan XN, Wang YY, et al. High-frequency cerebellar rTMS improves the swallowing function of patients with dysphagia after brainstem stroke. Neural Plast. 2022;2022:6259693.

95

Erfmann KLC, Macrae PR, Jones RD, et al. Effects of cerebellar transcranial direct current stimulation (tDCS) on motor skill learning in swallowing. Disabil Rehabil. 2022;44(11):2276-2284.

96

da Silva TR, de Carvalho Nunes HR, Martins LG, et al. Non-invasive brain stimulation can reduce unilateral spatial neglect after stroke: ELETRON trial. Ann Neurol. 2022;92(3):400-410.

97

Gorsler A, Grittner U, Rackoll T, et al. Efficacy of unilateral and bilateral parietal transcranial direct current stimulation on right hemispheric stroke patients with neglect symptoms: a proof-of-principle study. Brain Neurorehabil. 2022;15(2):e19.

98

Räty S, Ruuth R, Silvennoinen K, et al. Resting-state functional connectivity after occipital stroke. Neurorehabilitation Neural Repair. 2022;36(2):151-163.

99

Chu MM, Zhang YM, Chen JE, et al. Efficacy of intermittent theta-burst stimulation and transcranial direct current stimulation in treatment of post-stroke cognitive impairment. J Integr Neurosci. 2022;21(5):130.

100

Li W, Wen Q, Xie YH, et al. Improvement of poststroke cognitive impairment by intermittent theta bursts: a double-blind randomized controlled trial. Brain Behav. 2022;12(6):e2569.

101

Wang ZT, Li J, Wang XL, et al. Effect of transcranial direct-current stimulation on executive function and resting EEG after stroke: a pilot randomized controlled study. J Clin Neurosci. 2022;103:141-147.

102

Kathe C, Skinnider MA, Hutson TH, et al. The neurons that restore walking after paralysis. Nature. 2022;611(7936):540-547.

103

Rowald A, Komi S, Demesmaeker R, et al. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022;28(2):260-271.

104

Herrity AN, Aslan SC, Mesbah S, et al. Targeting bladder function with network-specific epidural stimulation after chronic spinal cord injury. Sci Rep. 2022;12(1):11179.

105

Lemos N, Fernandes GL, Ribeiro AM, et al. Rehabilitation of people with chronic spinal cord injury using a laparoscopically implanted neurostimulator: impact on mobility and urinary, anorectal, and sexual functions. Neuromodulation. 2023;26(1):233-245.

106

Handelman DA, Osborn LE, Thomas TM, et al. Shared control of bimanual robotic limbs with a brain-machine interface for self-feeding. Front Neurorob. 2022;16:918001.

107

Tonin L, Perdikis S, Kuzu TD, et al. Learning to control a BMI-driven wheelchair for people with severe tetraplegia. iScience. 2022;25(12):105418.

108

Mitchell P, Lee SCM, Yoo PE, et al. Assessment of safety of a fully implanted endovascular brain-computer interface for severe paralysis in 4 patients: the stentrode with thought-controlled digital switch (SWITCH) study. JAMA Neurol. 2023;80(3):270-278.

109

Blumberger DM, Mulsant BH, Thorpe KE, et al. Effectiveness of standard sequential bilateral repetitive transcranial magnetic stimulation vs bilateral Theta burst stimulation in older adults with depression: the FOUR-D randomized noninferiority clinical trial. JAMA Psychiatr. 2022;79(11):1065-1073.

110

Neacsiu AD, Beynel L, Graner JL, et al. Enhancing cognitive restructuring with concurrent fMRI-guided neurostimulation for emotional dysregulation-A randomized controlled trial. J Affect Disord. 2022;301:378-389.

111

Lee J, Lee CW, Jang Y, et al. Efficacy and safety of daily home-based transcranial direct current stimulation as adjunct treatment for bipolar depressive episodes: double-blind sham-controlled randomized clinical trial. Front Psychiatr. 2022;13:969199.

112

Hastings S, Zhong H, Feinstein R, et al. A pilot study combining noninvasive spinal neuromodulation and activity-based neurorehabilitation therapy in children with cerebral palsy. Nat Commun. 2022;13(1):5660.

113

He WJ, Huang Y, He L, et al. Safety and effects of transcranial direct current stimulation on hand function in preschool children with hemiplegic cerebral palsy: a pilot study. Front Behav Neurosci. 2022;16:925122.

114

Roeder BM, Riley MR, She XW, et al. Patterned hippocampal stimulation facilitates memory in patients with a history of head impact and/or brain injury. Front Hum Neurosci. 2022;16:933401.

115

Ahn JH, Lee D, Kim M, et al. M1 and cerebellar tDCS for MSA-C: a double-blind, randomized, sham-controlled, crossover study. Cerebellum. 2022:1-8.

116

Ni HC, Lin HY, Chen YL, et al. 5-day multi-session intermittent theta burst stimulation over bilateral posterior superior temporal sulci in adults with autism-a pilot study. Biomed J. 2022;45(4):696-707.

117

Maas RPPWM, Teerenstra S, Toni I, et al. Cerebellar transcranial direct current stimulation in spinocerebellar Ataxia type 3: a randomized, double-blind, sham-controlled trial. Neurotherapeutics. 2022;19(4):1259-1272.

118

Hara S, Andresen H, Solheim O, et al. Effect of spinal cord burst stimulation vs placebo stimulation on disability in patients with chronic radicular pain after lumbar spine surgery: a randomized clinical trial. JAMA. 2022;328(15):1506-1514.

119

Badhiwala JH, Wilson JR, Harrop JS, et al. Early vs late surgical decompression for central cord syndrome. JAMA Surg. 2022;157(11):1024-1032.

120

Javeed S, Dibble CF, Greenberg JK, et al. Upper limb nerve transfer surgery in patients with tetraplegia. JAMA Netw Open. 2022;5(11), e2243890.

121

Mitchell PJ, Yan B, Churilov L, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet. 2022;400(10346):116-125.

122

Fischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400(10346):104-115.

123

Peterschmitt MJ, Saiki H, Hatano T, et al. Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson's disease and a GBA mutation: results from part 1 of the randomized, double-blinded, placebo-controlled MOVES-PD trial. J Parkinsons Dis. 2022;12(2):557-570.

124

Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099-1109.

125

Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42-52.

126

Masson R, Mazurkiewicz-Bełdzińska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110-1119.

127

Hahn A, Günther R, Ludolph A, et al. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2022;17(1):276.

128

Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase Ⅲ SPR1NT trial. Nat Med. 2022;28(7):1381-1389.

129

Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase Ⅲ SPR1NT trial. Nat Med. 2022;28(7):1390-1397.

130

Whitehouse P, Gandy S, Saini V, et al. Making the case for accelerated withdrawal of aducanumab. J Alzheimers Dis. 2022;87(3):1003-1007.

131

DiStefano MJ, Alexander GC, Polsky D, et al. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: a nationally representative survey. J Am Geriatr Soc. 2022;70(6):1685-1694.

132

Haeberlein SB, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197-210.

133

van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.

134

The Lancet. Lecanemab for Alzheimer's disease: tempering hype and hope. Lancet. 2022;400(10367):1899.

135

Mahase E. Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns. BMJ. 2023;380:73.

136

Reardon S. FDA approves Alzheimer's drug lecanemab amid safety concerns. Nature. 2023;613(7943):227-228.

137

Lombardi G, Lombardi N, Bettiol A, et al. Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice. Eur J Clin Pharmacol. 2022;78(7):1155-1163.

138

Paganoni S, Hendrix S, Dickson SP, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022;93(8):871-875.

139

Aschenbrenner DS. New drug approved for ALS. Am J Nurs. 2023;123(1):22-23.

140

Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):11252.

141

Doenyas-Barak K, Catalogna M, Kutz I, et al. Hyperbaric oxygen therapy improves symptoms, brain's microstructure and functionality in veterans with treatment resistant post-traumatic stress disorder: a prospective, randomized, controlled trial. PLoS One. 2022;17(2), e0264161.

142

Hadanny A, Catalogna M, Yaniv S, et al. Hyperbaric oxygen therapy in children with post-concussion syndrome improves cognitive and behavioral function: a randomized controlled trial. Sci Rep. 2022;12(1):15233.

143

Gustavsson M, Kjörk EK, Erhardsson M, et al. Virtual reality gaming in rehabilitation after stroke - user experiences and perceptions. Disabil Rehabil. 2022;44(22):6759-6765.

144

Bach John R, Daniel W. Mechanical insufflation-exsufflation to facilitate ventilator weaning and possible decannulation for patients with encephalopathic conditions. J Neurorestoratol. 2023;11(1):100031.

145

Yang XF, Chen L, Pu JB, et al. Guideline of clinical neurorestorative treatment for brain trauma (2022 China version). J Neurorestoratol. 2022;10(2):100005.

146

Huang HY, Al Zoubi ZM, Moviglia G, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022). J Neurorestoratol. 2022;10(3):100015.

147

Huang H, Sharma H, Saberi H, et al. Spinal cord injury or dysfunction quality of life rating scale (SCIDQLRS) (IANR 2022 version). J Neurorestoratol. 2022;10(3):100016.

148

Moll G, Ankrum JA, Olson SD, et al. Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products. Stem Cells Transl Med. 2022;11(1):2-13.

149

Xiang SL, Guo WY, Peng HN, et al. Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China Version). J Neurorestoratol. 2020;8(4):197-216.

150

Pakzad M, Hassani SN, Abbasi F, et al. A roadmap for the production of a GMP-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications. Stem Cell Rev Rep. 2022;18(7):2279-2295.

Journal of Neurorestoratology
Article number: 100054
Cite this article:
Huang H, Bach JR, Sharma HS, et al. The 2022 yearbook of Neurorestoratology. Journal of Neurorestoratology, 2023, 11(2): 100054. https://doi.org/10.1016/j.jnrt.2023.100054

658

Views

11

Crossref

15

Web of Science

15

Scopus

Altmetrics

Received: 06 March 2023
Accepted: 07 April 2023
Published: 26 April 2023
© 2023 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Return